OnCo
peoplePerson

Jürgen Wolf

Built the Network Genomic Medicine that brought molecular testing to lung cancer patients across Germany, and led the capmatinib GEOMETRY trial.

Jürgen Wolf leads lung cancer research in Cologne and founded Network Genomic Medicine, which sequences NSCLC across hundreds of centres; he was principal investigator of GEOMETRY mono-1 (capmatinib in MET exon 14 disease).

Role
Medical Director, Lung Cancer Group Cologne; Head of Network Genomic Medicine
Specialisms
Lung cancerMolecular diagnostics networksMET and KRAS-targeted therapy
Profiles

Papers

1top
TitleJournalYear
Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer (GEOMETRY mono-1)NEJM2020

Key papers

1top
rctNew England Journal of Medicine 2023changed practice
DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer

Patients with small-cell lung cancer that has relapsed after chemotherapy now have a drug that works far better than topotecan or lurbinectedin, and it is the first T-cell engager approved for a solid tumour. Treatment requires inpatient monitoring for the first doses because of cytokine release syndrome, which most centres now manage on a short-stay basis. It does not yet apply to first-line treatment, where trials are ongoing.

Connected

6top

Pages like this

not linked directly; found by shared links

cancers

1
Non-small-cell lung cancer

technologies

1
Comprehensive genomic profiling

targets

1
MET

drugs

1
ApprovedSmall-molecule kinase inhibitors (MET)
Capmatinib & tepotinib · Tabrecta / Tepmetko

institutions

1
Uniklinik Köln (CIO)

key papers

1
DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer